125117-37-5Relevant articles and documents
Tautomerization of 2-acetylcyclohexanone. 1. Characterization of keto-enol/enolate equilibria and reaction rates in water
Iglesias, Emilia
, p. 2680 - 2688 (2003)
The keto-enol tautomerism of 2-acetylcyclohexanone (ACHE) was studied in water under different experimental conditions. By contrast with other previously studied β-diketones, the keto-enol interconversion in the ACHE system is a slow process. Under equilibrium conditions, the analysis of the absorbance readings of ACHE aqueous solutions yielded more than 40% of enol content at 25 °C; nevertheless, in aprotic solvents such as dioxane, ACHE is almost completely enolized. In alkaline medium, the enolate ion is the only existing species; the study of the effect of pH on the UV-absorption spectrum of ACHE yielded a value of 9.85 for the overall pKa of ACHE. Under nonequilibrium conditions, the keto-enol tautomerization was studied in water. Several factors affecting the reaction have been investigated, which include H+-catalysis, ionic strength effect, buffer catalysis, deuterium isotope effects, temperature effect, or solvent effects.
Solvent effects versus concentration effects in determining rates of base-catalyzed keto-enol tautomerization
Iglesias, Emilia
, p. 625 - 632 (2005)
Solvent effects of homogeneous media (such as solvent-water mixtures) on chemical reactivity may be interpreted as due to solvent polarity and/or molecular structure of solvent molecules. In microheterogeneous media (such as aqueous micellar solutions), solvent effects on reaction rates must include concentration effects, in addition to changes in the solvent polarity of the micelle interface where the reaction is assumed to occur. In this work, we measured the rates of keto-enol tautomerization of the 2-acetylcyclohexanone (ACHE) and 2-acetyl-1-tetralone (ATLO) systems in dimethylsulfoxide (DMSO)-water mixtures and in aqueous micellar solutions with both anionic and cationic surfactants and in the presence of buffers. The results appear as an ideal framework to understand the paramount importance of the specific molecular structure of solvent molecules in determining chemical reactivity versus solvent polarity or even concentration effects. The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2005.
Lanthanide triflate-promoted palladium-catalyzed cyclization of alkenyl β-keto esters and amides
Yang, Dan,Li, Jin-Heng,Gao, Qiang,Yan, Yi-Long
, p. 2869 - 2871 (2003)
(Matrix presented) Lanthanide triflates were found to promote the palladium-catalyzed cyclization of alkenyl β-keto esters and amides. In the presence of catalytic amounts of PdCl2(MeCN)2 and Ln(OTf)3, various alkenyl β-keto esters and amides underwent regioselective cyclization reactions to give six-, seven-, or eight-membered-ring carbocycles in moderate to excellent yields.
Evaluation of TCS/ZnCl2 with acetic anhydride as an acetylating reagent for methylene ketones
Elmorsy, Saad S.,Badawy, Doria S.,Khatab, Tamer K.
, p. 109 - 116 (2005)
A new route for the preparation of β-diketones which have applications in organic synthesis by the reaction of methylene ketones, acetic anhydride, TCS and ZnCl2 in the solvent methylene chloride at room temperature produces the corresponding β-diketones in excellent yield. Copyright Taylor & Francis Inc.
Discovery of quinolone derivatives as antimycobacterial agents
Gao, Chao,Li, Xiao,Liu, Kun-Lin,Teng, Fei,Xiong, Lu,Yu, Luo-Ting
, p. 24095 - 24115 (2021)
Tuberculosis (TB), an infectious disease caused byMycobacterium tuberculosis(M. tuberculosis), is an important public health issue. Current first-line drugs administered to TB patients have been in use for over 40 years, whereas second-line drugs display strong side effects and poor compliance. Additionally, designing effective regimens to treat patients infected with multi- and extremely-drug-resistant (MDR and XDR) strains of TB is challenging. In this report, we screened our compound library and identified compound1with antituberculosis activity and a minimal inhibitory concentration (MIC) againstM. tuberculosisof 20 μg mL?1. Structure optimization and the structure-activity relationship of1as the lead compound enabled the design and synthesis of a series of quinolone derivatives,6a1-6a2,6b1-6b36,6c1,6d1-6d14,7a1-7a2,7b1-7b2,7c1,8a1-8a5,9a1-9a4and10a1-10a6. These compounds were evaluatedin vitrofor anti-tubercular activity against theM. tuberculosisH37Rv strain. Among them, compounds6b6,6b12and6b21exhibited MIC values in the range of 1.2-3 μg mL?1and showed excellent activity against the tested MDR-TB strain (MIC: 3, 2.9 and 0.9 μg mL?1, respectively). All three compounds were non-toxic toward A549 and Vero cells (>100 and >50 μg mL?1, respectively). In addition, an antibacterial spectrum test carried out using compound6b21showed that this compound specifically inhibitsM. tuberculosis. These can serve as a new starting point for the development of anti-TB agents with therapeutic potential.
Pyridone derivative and application thereof in preparation of medicine for preventing and/or treating tuberculosis caused by Mycobacterium tuberculosis
-
, (2021/07/01)
The invention provides a pyridone derivative and application thereof in preparation of a medicine for preventing and/or treating tuberculosis caused by mycobacterium tuberculosis, which belong to the field of pharmacy. The structure of the pyridone derivative is shown as a formula (I). Experimental results show that the pyridone derivative provided by the invention can specifically inhibit the activity of mycobacterium tuberculosis, has small toxic and side effects, can be used for preparing a medicine for resisting mycobacterium tuberculosis, can also be used for preparing a medicine for preventing and/or treating tuberculosis, and a new choice is provided for medicines for treating tuberculosis (especially drug-resistant tuberculosis).
SKLB1039 Compound as well as preparation method and application thereof
-
Paragraph 0030; 0039; 0065-0069, (2021/10/27)
The invention belongs to the technical field of preparation of new compounds, and particularly relates SKLB1039 compound as well as a preparation method and application thereof. The 2 -methyl -3 -nitrobenzoic acid is taken as an initial raw material and is brominated. Esterification, reduction, reductive amination and hydrolysis synthesis 5 - bromo -2 - methyl -3 - (N - ethyl, N - (tetrahydropyran -4 - yl)) aminobenzoic acid. The cyclohexanone serving as a raw material is subjected to catalytic hydrogenation reduction of carbonyl α, acetyl cyclohexanone and cyanopyridone to synthesize 4 - aminomethyl -1 - methyl -5, 6, 7, 8 - tetrahydroisoquinoline -3 (2H) - ketone. Coupling the two to an amide is followed by catalytic coupling with an aryl sheet to give SKLB1039 a compound. SKLB1039 Large-scale preparation technology is provided, operation is easy, the post-treatment purification process is simple, the total route yield is improved, raw materials are easy to purchase, the price is low, and the production cost is greatly reduced.
ONE-STEP, FAST, 18F-19F ISOTOPIC EXCHANGE RADIOLABELING OF DIFLUORO-DIOXABORININS AND USE OF SUCH COMPOUNDS IN TREATMENT
-
Paragraph 0019; 0202-0203, (2019/12/15)
A compound according to Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X1 and X2 are each independently 18F or 19F; R1 and R2 are each independently alkyl, amine, perfluoroalkyl, alkenyl, alkynyl, aryl, or aralkenyl; and R3 is H, halo, alkyl, alkyl ester, alkenyl, alkynyl, aryl, or aralkenyl; or wherein: R1 and R3 or R2 and R3 join to form a 6-membered cycloalkyl or heterocyclyl; or R1 and R3, R2 and R3, or R1, R2, and R3 join to form a substituted or unsubstituted polycyclic ring, wherein the polycyclic ring comprises fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl rings.
One-pot method for preparation of 2-acetyl cyclohexanone
-
Paragraph 0009; 0024-0027, (2017/05/27)
The invention discloses a one-pot method for preparation of 2-acetyl cyclohexanone. The method comprises the steps of: (1) adding cyclohexanone into tetrahydrofuran, under the condition of icewater bath cooling, adding lithium diisopropylamide dropwise, and then carrying out stirring reaction at room temperature for 1h; (2) under the condition of icewater bath, adding a trichloromethane solution of acetyl chloride into the reaction system of step (1) dropwise, then removing icewater bath, and carrying out stirring reaction at room temperature for 1h; and (3) washing the reaction solution obtained in step (2) twice and performing liquid separation, conducting spin drying of trichloromethane, then carrying out pressure reduced distillation and collecting 118-136DEG C fractions, thus obtaining 2-acetyl cyclohexanone. According to the method, in the whole reaction process, the intermediate products have no need for additional purification treatment and can be directly subjected to next step reaction, and the finally obtained product is refined directly by pressure reduced distillation. The whole process has the advantages of high yield, short reaction time, and low energy consumption. The 2-acetyl cyclohexanone obtained by direct pressure reduced distillation refining has a concentration of more than 96.0wt%, and the yield is more than 94%.
Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors
Zhang, Lidan,Song, Xuejiao,Wang, Ningyu,Zhao, Lifeng,Feng, Qiang,You, Xinyu,Peng, Cuiting,Gao, Tiantao,Xiong, Menghua,He, Bing,Gao, Chao,Luo, Yong,Xu, Ying,Zhang, Qiyi,Yu, Luoting
, p. 25967 - 25978 (2015/10/20)
The histone lysine methyltransferase EZH2 has been implicated as a key component in cancer aggressiveness, metastasis and poor prognosis. This study discovered a new class of hexahydroisoquinolin derivatives as EZH2 inhibitors. A structure-activity relationship study showed that the steric hindrance was important to the activity for EZH2. A preliminary optimization study led to the discovery of several potent compounds with low nanomolar to sub-nanomolar potency for EZH2. Biological evaluation indicated that SKLB1049 was a highly potent with improved solubility compared to EPZ6438, SAM-competitive, and cell-active EZH2 inhibitor that decreased global H3K27me3 in SU-DHL-6 and Pfeiffer lymphoma cells in a concentration- and time-dependent manner. Further study indicated that SKLB1049 caused cell arrest in G0/G1 phase. These compounds would be useful as chemical tools to further explore the biology of EZH2 and provided us with a start point to develop new EZH2 inhibitors.
